Together, cancer meets its match
Omico is changing the way we fight cancer by accelerating access to precision oncology. We are a national, independent, not-for-profit organisation, uniting Australia’s world-class cancer institutes, researchers, clinicians, industry partners and government like never before. By leveraging a nationwide network of expertise and resources, we aim to improve outcomes for all Australian cancer patients. With fast-tracked molecular and genomic screening, biomarker-led trial set up and patient enrolment from the entire nation, we’re accelerating access to next generation treatments and preventive strategies.
What we do
We aim to improve outcomes for Australians living with cancers, by:
- Increasing access to genomic profiling to detect unique genetic variations in cancer patients’ tumours to identify potential matches to new targeted treatments options
- Growing and streamlining biomarker-led clinical trials by expediting patient recruitment and site setup, and attracting more international trials to Australia, facilitating faster transitions from discovery to clinical application
- Advancing a research-led model of care as to open new treatment pathways for patients, and supporting drug development and cancer research through the collection of real-world data
How our molecular screening works
If you or someone you know has advanced or incurable cancer or is at high-risk for cancer (due to hereditary conditions) then:
- Your doctor completes an online referral form
- You sign a consent form
- Omico assesses the genes and other molecules in your cancer tissue
- Our experts match results to an existing therapy or clinical trial of a new drug
- Process takes 8 to 10 weeks
Researchers
Meet intellectually-stimulating research that changes cancer care and transforms lives.
Clinicians
Meet accelerated access to innovative new therapies for your patients.
Government
Meet an opportunity to advance the nation’s health and wealth.
Advocacy Groups
Meet a partner that can help you make a real difference for those affected by cancer.
Who we work with
Recent news
Omico Working Together with Australian Cancer Patient Advocacy Groups
Sydney, Australia – April 18, 2024 - Omico recognises that patient advocacy organisations are experts in understanding the patient, family and community experience with cancer, tailoring information, and support, and advocating for equity of access to the latest advances in diagnosis, treatment and care.
Unlocking the Power of Real-World Data at Omico
Sydney, Australia – April 12, 2024 - With respect to our landmark initiative PrOSPeCT, supporting Omico on this journey are two key partners, Quantium and Australia's largest supercomputing centre, National Computational Infrastructure (NCI Australia). Quantium is well known in the data science and artificial intelligence space and assists by providing its advanced analytical firepower. In parallel, NCI provides a secure and protected environment to house data from PrOSPeCT and a powerful platform for sharing data to enable the analysis of large quantities of genomic information, effectively bringing precision medicine to real-world data.
Omico’s National Clinical Trials Network
Sydney, Australia – April 18, 2024 - Omico is dedicated to advancing cancer treatment and care by establishing and supporting a network of clinical trial sites. Coordinated by Lucille Sebastian, the Omico National Clinical Trials Network (ONCTN), aims to broaden treatment options to patients whilst improving equitable access to clinical trials. This endeavour involves collaboration with various stakeholders including clinical trial units, clinicians, patients, and pharmaceutical companies.